Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
Diphosphates
DNA Mismatch Repair
Endometrial Neoplasms
Female
Humans
Ligands
Neoplasm Recurrence, Local
Phthalazines
Ribose

authors with profiles

John Moroney
Gini Fleming